EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Performance of Donor‐Derived Cell‐Free DNA in Surveillance and For‐Cause Biopsies in Pediatric Kidney Transplant Recipients

Stella Kilduff, Joseph Fishbein, Carlos Becerril‐Romero, Matthew Switalski, Debora Matossian, Priya S. Verghese

Pediatric Transplantation · 2025-12 · 29 (8)

DOI: 10.1111/petr.70215 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background Donor‐derived cell‐free DNA (dd‐cfDNA), a biomarker demonstrated to increase with allograft injury, has been considered a possible diagnostic tool for allograft rejection in place of the current gold standard which is invasive kidney biopsies. We tested whether dd‐cfDNA levels were predictive of rejection in our single‐center cohort of pediatric kidney transplant (KT) recipients. Methods All primary pediatric KT recipients that had a dd‐cfDNA level obtained within a month of any kidney biopsy, either surveillance or for‐cause were included. Descriptive analysis was performed stratified by rejection status. Univariate analysis was performed to assess the association between median dd‐cfDNA levels and rejection by each biopsy time point. dd‐cfDNA levels were then further stratified by rejection type (no rejection, T‐cell mediated, antibody mediated, or mixed). Diagnostic performance metrics of dd‐cfDNA for detecting rejection were evaluated. Results Forty pediatric KT recipients had 44 biopsies, 21 (48%) of which demonstrated rejection. Acute cellular, antibody‐mediated, and mixed rejection occurred in 12 (57%), 6 (29%), and 3 (14%) respectively. The median dd‐cfDNA level at the time of biopsy in those with and without rejection was 1.7 (95% CI: 0.2, 3.3) and 0.3 (95% CI: 0.2, 0.7), respectively ( p = 0.15). dd‐cfDNA levels prior to for‐cause biopsies were significantly higher in patients with rejection (0.3 vs. 2.7; p = 0.02). dd‐cfDNA levels at surveillance biopsies did not differ significantly by rejection status or type of rejection. dd‐cfDNA levels ≥ 1 diagnosed rejection with a sensitivity of 52% and specificity of 83%. Conclusions Elevated dd‐cfDNA levels were associated with rejection in for‐cause biopsies but not in surveillance biopsies.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →